Lantus (Insulin Glargine) for Older Adults 65+: Transitioning to Adult Care

Why Transitioning to Adult Care Matters for Older Adults on Lantus

The shift from one care model to another, whether from pediatric endocrinology to adult medicine or from hospital-based diabetes management to outpatient primary care, introduces real clinical hazards for patients over 65 using long-acting insulin. Dose errors, missed monitoring appointments, and communication failures between care teams account for a significant share of insulin-related adverse events in this age group.

The FDA's 2016 safety communication on insulin errors identified older adults as disproportionately affected by wrong-dose and wrong-type errors during care transitions, particularly in the 30-day window following a care handoff (FDA Drug Safety Communication, 2016).

What Changes Physiologically After Age 65

Insulin clearance slows with age. Renal function declines at roughly 1 mL/min/1.73m² per year after age 40, and glomerular filtration rate directly affects how long insulin glargine remains active in the bloodstream (NCBI review on insulin pharmacokinetics in aging, 2018). A patient who was stable on 28 units of Lantus at age 60 may experience prolonged insulin action and cumulative hypoglycemia at 68 on the same dose.

Body composition shifts also matter. Older adults tend to gain visceral fat while losing lean muscle mass, which changes insulin sensitivity in ways that are not always reflected in HbA1c alone.

The 30-Day Transition Window

The 30 days following any care handoff carry the highest risk. A 2019 analysis published in JAMA Internal Medicine found that adults over 65 discharged from hospital with insulin were 2.7 times more likely to visit an emergency department within 30 days compared to those on non-insulin glucose-lowering agents (JAMA Intern Med, 2019). A structured 30-day post-transition follow-up, either in-person or via telehealth, is the single most effective intervention to catch dose errors early.

ADA and AACE Guidelines on Basal Insulin in Older Adults

The American Diabetes Association's Standards of Medical Care in Diabetes (2024 edition) dedicates Section 13 specifically to older adults. The document states directly: "Glycemic goals should be individualized on the basis of patient characteristics such as functional status, comorbidities, and life expectancy" (ADA Standards 2024, Section 13).

HbA1c Targets by Functional Status

The ADA stratifies older adults into three categories for glycemic target-setting:

• Healthy older adults with few comorbidities and intact cognition: HbA1c target <7.0 to 7.5%
• Adults with multiple chronic conditions or mild-to-moderate cognitive impairment: HbA1c target <8.0%
• Adults with very complex health status, end-stage disease, or residing in long-term care: HbA1c target <8.5%, with avoidance of symptomatic hyperglycemia as the primary goal

These targets exist because tight glycemic control below 7.0% in older frail adults has not been shown to reduce cardiovascular or mortality outcomes, while it substantially increases severe hypoglycemia events. The ACCORD trial (N=10,251) demonstrated a 22% increase in all-cause mortality in the intensive glycemic control arm (mean HbA1c 6.4%) compared to standard control (NEJM, 2008).

AACE Guidance on Insulin Selection

The American Association of Clinical Endocrinology notes that second-generation basal insulins, specifically insulin glargine 300 units/mL (Toujeo) and insulin degludec (Tresiba), show lower nocturnal hypoglycemia rates compared to glargine 100 units/mL (Lantus) in older adults. The EDITION 3 trial (N=549, type 2 diabetes on oral agents) found Toujeo produced 23% fewer nocturnal hypoglycemia events versus Lantus U-100 over 6 months (Diabetes Care, 2015). For patients 65 and older with history of nocturnal hypoglycemia, clinicians may consider switching from Lantus U-100 to Toujeo as part of the care transition plan.

Safe Dosing and Titration of Lantus in Geriatric Patients

Starting conservatively protects against the most common transition error: carrying over a hospital dose into an outpatient setting without accounting for reduced activity levels, changed diet, or improved medication adherence now that the patient is home.

Starting Dose Recommendations

For insulin-naive older adults with type 2 diabetes, the standard starting dose is 10 units/day or 0.1 to 0.2 units/kg/day, whichever is lower (FDA Lantus Prescribing Information). For patients over 75 or with an eGFR <45 mL/min/1.73m², starting at 6 to 8 units/day and titrating slowly is prudent.

Titration Protocol

The validated "2-2-2" titration approach works well in geriatric outpatient settings:

• Increase by 2 units every 3 days if fasting glucose remains above 130 mg/dL
• Hold titration if any fasting glucose reading falls below 80 mg/dL
• Reduce the current dose by 10 to 20% at the first confirmed hypoglycemic episode (glucose <70 mg/dL)

This approach mirrors the treat-to-target method used in the LANMET trial, which demonstrated that self-titrated glargine produced HbA1c reductions of 1.7% over 36 weeks without increasing severe hypoglycemia rates compared to NPH insulin (Diabetologia, 2006).

Renal Dosing Considerations

Insulin glargine is metabolized partly by the kidneys. As eGFR declines, insulin half-life extends and hypoglycemia risk climbs. A PubMed-indexed review of insulin use in chronic kidney disease found that patients with eGFR <30 mL/min/1.73m² may require 25 to 50% dose reductions compared to their pre-CKD baseline (Am J Kidney Dis, 2012). Routine eGFR monitoring every 3 to 6 months is appropriate for older adults on Lantus with any degree of CKD.

Hypoglycemia Risk: The Central Safety Issue in Older Adults

Hypoglycemia is not a minor inconvenience in patients over 65. It triggers cardiac arrhythmias, contributes to falls and fractures, and is independently associated with dementia progression. A large retrospective cohort study published in BMJ (N=205,000 adults with type 2 diabetes) found that a single episode of severe hypoglycemia requiring hospitalization was associated with a 2.4-fold increased risk of dementia over the following 5 years (BMJ, 2012).

Recognizing Blunted Hypoglycemia Symptoms in Older Adults

Older adults frequently lose the classic adrenergic warning symptoms of hypoglycemia, including sweating, tremor, and palpitations. Instead, they present with confusion, dizziness, or sudden behavioral change. This phenomenon, called hypoglycemia unawareness, affects an estimated 25% of older adults on insulin and makes glucose monitoring even more critical during transitions (Endocrine Reviews, 2019).

Continuous Glucose Monitoring as a Transition Safety Tool

Continuous glucose monitoring (CGM) dramatically reduces hypoglycemia burden in older insulin users. The DIAMOND trial demonstrated that CGM reduced severe hypoglycemia events by 39% compared to standard fingerstick monitoring in adults with type 1 diabetes over 24 weeks (Lancet, 2017). Initiating CGM at the time of a care transition gives the receiving clinical team a 14-day retrospective glucose trace, making dose errors visible before they cause harm.

Medicare Part B covers CGM for beneficiaries requiring insulin at least three times daily, but the coverage criteria were broadened in 2023 to include patients on basal insulin alone who meet therapeutic necessity criteria (CMS CGM Coverage, 2023).

Cognitive and Functional Screening Before Adjusting Lantus

Before adjusting any insulin regimen during a care transition, the receiving clinician needs a baseline picture of the patient's cognitive and functional status. A patient with mild cognitive impairment may not reliably administer injections, report symptoms, or follow titration instructions.

Screening Tools to Use at Transition

The Mini-Cog (3-item recall plus clock drawing) takes under 3 minutes and identifies cognitive impairment with 76% sensitivity in primary care settings (Alzheimer's Dement, 2015). The Clinical Frailty Scale (CFS) is a 9-point scale that stratifies patients from very fit to terminally ill and directly informs glycemic target selection. Patients scoring CFS 5 or higher (mildly frail to severely frail) should generally be managed at the more relaxed HbA1c targets described in the ADA Section 13 framework above.

Caregiver and Social Support Assessment

Many older adults depend on a caregiver to administer Lantus. The transition handoff must document who is performing injections, whether that person has received formal injection training, and whether insulin storage conditions at home are adequate. Insulin glargine degrades above 77°F (25°C) and loses potency when exposed to light for extended periods (FDA Lantus Prescribing Information). Patients or caregivers who are not aware of these storage requirements may be using degraded insulin without knowing it, which can masquerade as insulin resistance.

Structuring the Clinical Handoff for Older Adults on Lantus

A care transition is a procedural event, not just a referral. The components below constitute a minimum-safe handoff for any geriatric patient on basal insulin.

The Five-Element Lantus Transition Checklist

1. Medication reconciliation. Confirm current Lantus dose, formulation (U-100 vs. U-300), injection time (morning vs. Evening), and pen or vial type. Dose confusion between Lantus U-100 and Toujeo U-300 has caused 3-fold overdose errors and is documented in FDA MedWatch reports.

2. Updated eGFR and most recent HbA1c. Both values should be no older than 90 days at the time of transition. If eGFR has dropped by more than 15 mL/min/1.73m² since the last dose adjustment, proactive dose reduction is appropriate before the first outpatient visit.

3. CGM or glucose log review. A minimum of 14 days of glucose data, from either a CGM download or a paper log, should accompany the patient to the receiving provider. Time-in-range (70 to 180 mg/dL) below 50% signals that the current regimen needs adjustment.

4. Hypoglycemia history. Document any episodes in the prior 6 months, whether confirmed by glucose reading or symptom-based, along with whether the patient required glucagon rescue or emergency services.

5. 30-day follow-up appointment. Schedule before the patient leaves the handoff visit. The ISMP (Institute for Safe Medication Practices) has specifically identified lack of follow-up scheduling as a root cause in insulin-related adverse events during care transitions (ISMP Medication Safety Alert, 2016).

Telehealth as a Transition Bridge

For older adults with limited mobility or transportation barriers, a telehealth check-in at 2 weeks post-transition allows dose review without requiring an in-person visit. CGM devices that upload data automatically to a cloud platform (Dexcom CLARITY, LibreView) allow the receiving clinician to review glucose trends remotely before that call. The ADA's 2024 Standards endorse telehealth-delivered diabetes management as equivalent to in-person care for stable patients (ADA Standards 2024).

Drug Interactions and Polypharmacy Considerations

Adults over 65 take an average of 5.8 prescription medications, creating a high-risk environment for insulin interactions (CDC National Health Statistics, 2022). Several drug classes commonly used in older adults directly affect Lantus activity.

Medications That Increase Hypoglycemia Risk with Lantus

Beta-blockers mask adrenergic hypoglycemia symptoms and blunt the counter-regulatory glucagon response. Patients newly started on metoprolol or carvedilol during a hospitalization may arrive at their first outpatient visit with blunted hypoglycemia awareness they did not have before. ACE inhibitors and ARBs improve insulin sensitivity and may require a 5 to 10% reduction in basal insulin dose. Fluoroquinolone antibiotics, particularly levofloxacin, can cause both hypoglycemia and hyperglycemia and should prompt extra glucose monitoring for the duration of the course (FDA Drug Safety Communication, Fluoroquinolones, 2013).

Medications That Increase Hyperglycemia Risk with Lantus

Corticosteroids are the most common culprit. A patient starting prednisone for a COPD exacerbation or joint inflammation may see fasting glucose rise by 50 to 100 mg/dL within 48 hours. For patients on short-course steroids (<2 weeks), a temporary 20% Lantus dose increase with daily monitoring is a practical approach that avoids persistent dose changes after the steroid course ends.

Patient Education Priorities at the Point of Transition

Education delivered at one clinic does not automatically transfer with the patient. The receiving team should treat education as starting from scratch.

Injection Technique Review

Lipohypertrophy, the subcutaneous fat buildup from repeated injections at the same site, affects an estimated 30 to 50% of long-term insulin users and causes erratic insulin absorption (Diabetes Metab, 2016). The transition visit should include a brief injection site inspection and a rotation protocol review.

Hypoglycemia Action Plan

Every patient on Lantus over 65 should leave the transition visit with a written hypoglycemia action plan that includes:

• A glucose threshold for treatment (typically <70 mg/dL)
• The 15-15 rule: 15 grams of fast-acting carbohydrates, recheck in 15 minutes
• When to call the clinical team vs. When to call 911
• Glucagon kit or nasal glucagon (Baqsimi) prescription and caregiver training

Nasal glucagon (Baqsimi 3 mg) is approved by the FDA for severe hypoglycemia in patients 4 years and older and is particularly practical for older adults whose caregivers may struggle with reconstituting injectable glucagon under stress (FDA Baqsimi Approval, 2019).

Monitoring Schedule After Transition

Monitoring frequency should increase temporarily during the 60 days following any care transition, then settle into a maintenance schedule once the patient and regimen are stable.

First 60 Days Post-Transition

• Fasting glucose daily (fingerstick or CGM)
• 2-hour post-meal glucose at least 3 times per week if postprandial control is a concern
• eGFR and comprehensive metabolic panel at 30 days
• HbA1c at 60 to 90 days to capture the net effect of any dose adjustments made at transition

Ongoing Maintenance Schedule

• HbA1c every 3 months if any regimen change was made in the prior 6 months; every 6 months once stable
• eGFR every 6 months for patients with baseline CKD stage 2 or higher
• Annual ophthalmology and podiatry referrals per ADA microvascular complication screening guidelines (ADA Standards 2024)